


## PHARMACEUTICAL 2021



## BridgeBio Pharma Inc. Rank 312 of 402





## PHARMACEUTICAL 2021



BridgeBio Pharma Inc. Rank 312 of 402

The relative strengths and weaknesses of BridgeBio Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BridgeBio Pharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 23% points. The greatest weakness of BridgeBio Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is -45%, being 92% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	642,824
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	95,648
Liabilities, Non-Current	116,618
Other Assets	40,439
Other Compr. Net Income	56,702
Other Expenses	0
Other Liabilities	383,436
Other Net Income	-31,006
Other Revenues	8,249
Property and Equipment	20,325
Research and Development	337,047
Selling, General and Administrative Expense	145,684

Output Variable	Value in 1000 USD
Assets	703,588
Liabilities	595,702
Expenses	482,731
Revenues	8,249
Stockholders Equity	107,886
Net Income	-505,488
Comprehensive Net Income	-477,137
Economic Capital Ratio	-45%

